Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 14, 2026, 7:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 3,322 matching trials from the live ClinicalTrials.gov search.
Conditions
Metastatic Pancreatic Carcinoma
Interventions
gemcitabine, capecitabine, erlotinib
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Tampa, Florida
Conditions
Cystic Fibrosis
Interventions
Ophthalmologic examinations, Ivacaftor Exposed
Other · Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
6 Years to 11 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
38
States / cities
Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 35 more
Conditions
Pancreatic Cancer
Interventions
bevacizumab, cisplatin, gemcitabine hydrochloride
Biological · Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
San Francisco, California
Conditions
Neuroendocrine Tumors, Neuroendocrine Tumor of the Lung, Neuroendocrine Tumor Grade 1, Neuroendocrine Tumor Grade 2, Neuroendocrine Tumor of Pancreas
Interventions
[212Pb] VMT-α-NET, [203Pb] VMT-α-NET SPECT/CT
Drug · Diagnostic Test
Lead sponsor
David Bushnell
Other
Eligibility
18 Years to 80 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Conditions
Congenital Hyperinsulinism, Insulinoma
Interventions
Fluorodopa F 18
Drug
Lead sponsor
Cook Children's Health Care System
Other
Eligibility
Up to 18 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2028
U.S. locations
1
States / cities
Fort Worth, Texas
Conditions
Metastatic Pancreatic Cancer
Interventions
RX-3117
Drug
Lead sponsor
Processa Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
10
States / cities
Tucson, Arizona • Weeki Wachee, Florida • Joliet, Illinois + 7 more
Conditions
Cystic Fibrosis, Ventilatory Defect
Interventions
19F MRI
Combination Product
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Conditions
Metastatic Malignant Neoplasm
Interventions
NPX267
Drug
Lead sponsor
NextPoint Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
7
States / cities
Baltimore, Maryland • Boston, Massachusetts • New York, New York + 4 more
Conditions
Pancreatic Cancer
Interventions
FOLFOXA
Drug
Lead sponsor
Brown University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
2
States / cities
Providence, Rhode Island
Conditions
Duct Cell Adenocarcinoma of the Pancreas, Stage III Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions
gemcitabine hydrochloride, fluorouracil, radiation therapy, laboratory biomarker analysis
Drug · Radiation · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Pancreatic Cancer Non-resectable
Interventions
Folfirinox, Stereotactic Body Radiation Therapy
Drug · Radiation
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Cystic Fibrosis, Fatigue
Interventions
CF Wellness Program Sessions
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland • Seattle, Washington
Completed Not applicable Interventional Results available

FDG-PET Imaging in Young Cystic Fibrosis Patients

NCT00846053
Conditions
Cystic Fibrosis
Interventions
FDG-PET
Diagnostic Test
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 21 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Type 1 Diabetes Mellitus
Interventions
Web Simulation Tool (WST), Behavioral Adaptation Module (BAM), Auto Titration Module (ATM), Automated Insulin Delivery (AID) System
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
Cystic Fibrosis, Pseudomonas Aeruginosa
Interventions
AZLI
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Up to 12 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
10
States / cities
Aurora, Colorado • Jacksonville, Florida • Chicago, Illinois + 7 more
Conditions
Advanced Solid Tumor, RAS Mutation, RAF Mutation, NF1 Mutation
Interventions
ABM-168
Drug
Lead sponsor
ABM Therapeutics Corporation
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
6
States / cities
San Francisco, California • Indianapolis, Indiana • New Brunswick, New Jersey + 3 more
Conditions
Epstein-Barr Virus+ Associated Post-transplant Lymphoproliferative Disease (EBV+ PTLD), Solid Organ Transplant Complications, Lymphoproliferative Disorders, Allogeneic Hematopoietic Cell Transplant, Stem Cell Transplant Complications
Interventions
tabelecleucel
Biological
Lead sponsor
Pierre Fabre Medicament
Industry
Eligibility
Not listed
Enrollment
115 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2030
U.S. locations
40
States / cities
Duarte, California • La Jolla, California • Loma Linda, California + 28 more
Conditions
Chronic Pancreatitis
Interventions
Questionnaires
Behavioral
Lead sponsor
Methodist Health System
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Type 1 Diabetes
Interventions
RocketAP, USS Virginia
Device
Lead sponsor
University of Virginia
Other
Eligibility
12 Years to 25 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Conditions
COPD, Cystic Fibrosis, Pulmonary Fibrosis
Interventions
Plerixafor mobilization of autologous CD117 stem cells
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Completed Not applicable Interventional Results available

SpHincterotomy for Acute Recurrent Pancreatitis

NCT03609944
Conditions
Pancreatitis, Pancreas Divisum, Pancreatitis, Acute, Pancreatitis Idiopathic, Pancreas Inflamed
Interventions
ERCP with miES, EUS
Procedure
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
20
States / cities
Little Rock, Arkansas • Los Angeles, California • San Francisco, California + 16 more
Conditions
Cystic Fibrosis Related Diabetes, Pancreatic Insufficiency
Interventions
placebo, repaglinide
Drug
Lead sponsor
Arbelaez, Ana Maria
Individual
Eligibility
12 Years to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2013
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Cystic Fibrosis, Exocrine Pancreatic Insufficiency
Interventions
EUR-1008 (APT-1008)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Up to 12 Months
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
6
States / cities
Jacksonville, Florida • Las Vegas, Nevada • Akron, Ohio + 3 more
Completed Phase 2Phase 3 Interventional Results available

Semaglutide in CFRD

NCT05788965
Conditions
Cystic Fibrosis, Cystic Fibrosis-related Diabetes
Interventions
Semaglutide
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Minneapolis, Minnesota